Margarita Chavez
Chairperson @ Xylo Bio
North Chicago, United States
Margarita Chavez is a Series A investor at Xylo Bio in North Chicago focused on Biotechnology and Health Care. Margarita Chavez is based out of Chicago, Illinois and is the Chairperson of Xylo Bio. Margarita previously worked at Wellington Life Science Partners as a Venture Partner. Margarita Chavez attended the Santa Clara University.
- Total investments:
- 15
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Margarita Chavez invests in
Stages Margarita Chavez invests in
Countries Margarita Chavez invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (27%)
- Health Care 3 (20%)
- Life Science 3 (20%)
- Therapeutics 2 (13%)
- Medical 1 (7%)
Stage
- Series A 3 (20%)
- Seed 1 (7%)
- Series B 1 (7%)
- Series C 1 (7%)
- Venture - Series Unknown 1 (7%)
Country
- United States 2 (13%)
- Italy 1 (7%)
- Australia 1 (7%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Carisma Therapeutics
|
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $30M / Series C / Sep 21, 2022 | |
Nitrase Therapeutics
|
Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is onParkinson's disease, the company aims to expand its proprietary platform to include other disease indications. | $7M / Series A / Nov 02, 2021 | |
|
Nitrase Therapeutics
|
Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is onParkinson's disease, the company aims to expand its proprietary platform to include other disease indications. | $7M / Series A / Nov 02, 2021 | |
|
Carisma Therapeutics
|
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $12M / Series B / Mar 01, 2021 | |
|
Carisma Therapeutics
|
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $47M / Series B / Jan 07, 2021 | |
Enthera
|
Enthera S.r.l. is a new Italian biotech start-up which mission is to find new therapeutic approaches to treat diabetes and related gastrointestinal complication (enteropathy), as well as other intestinal disorders sharing the same biological pathway. Its name comes from the crasis of the terms entero (referring to the intestine) and therapy.Enthera was founded by BiovelocITA in October 2016 in collaboration with the scientists: Prof. Paolo Fiorina and Dr. Francesca D’Addio. | $32.8M / Series A / Jul 28, 2020 | |
|
Enthera
|
Enthera S.r.l. is a new Italian biotech start-up which mission is to find new therapeutic approaches to treat diabetes and related gastrointestinal complication (enteropathy), as well as other intestinal disorders sharing the same biological pathway. Its name comes from the crasis of the terms entero (referring to the intestine) and therapy.Enthera was founded by BiovelocITA in October 2016 in collaboration with the scientists: Prof. Paolo Fiorina and Dr. Francesca D’Addio. | $32.8M / Series A / Jul 28, 2020 | |
|
Nitrase Therapeutics
|
Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is onParkinson's disease, the company aims to expand its proprietary platform to include other disease indications. | $38M / Series A / Apr 22, 2020 | |
|
Nitrase Therapeutics
|
Nitrase Therapeutics is a platform company developing drugs against a newly identified class of enzymes called Nitrases, initially targeting Parkinson’s disease. The therapies that Nitrome is developing will target these enzymes and potentially help slow or halt the progression of diseases such as Parkinson’s. While the initial focus is onParkinson's disease, the company aims to expand its proprietary platform to include other disease indications. | $38M / Series A / Apr 22, 2020 | |
|
Carisma Therapeutics
|
Carisma Therapeutics is a biotechnology company developing cellular immunotherapies to treat solid tumors. Its cell therapies apply powerful chimeric antigen receptor technology and adoptive cell transfer in cancer therapy and to macrophages that infiltrate the solid tumor micro-environment that enables solid tumor patients to receive strongcellular immunotherapy and cancer treatments. The company's technology leverages advances in macrophage biology, chimeric antigen receptor engineering, and adoptive cellular therapy for the treatment of human disease.Founded in 2016 by Michael Klichinsky and Saar Gill, Carisma Therapeutics is headquartered in Philadelphia, Pennsylvania. | $6M / Series A / Aug 08, 2019 | |
| See all 15 investments → | |||
Co-Investors
About Xylo Bio
Xylo Bio is a drug development company that focuses on next-generation psychedelics. With psychedelic molecules as the starting point, our goal is to develop medicines that are widely available as improved treatments to currently available SSRI medications.
Xylo Bio Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Margarita Chavez
Chairperson
|
|||
Joshua Ismin
Co-Founder & President
|
|||
Sam Banister
CSO & Co-Founder
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Margarita Chavez invest in?
Margarita Chavez invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Seed stage. Most of the 15 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Margarita Chavez?
Public channels for Margarita Chavez include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Margarita Chavez last invest?
The most recent investment recorded for Margarita Chavez closed in Sep 2022. Shizune tracks 15 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Sep 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
